Document is current
Any future updates will be listed below
-
Authors
Koller, Paul https://orcid.org/0000-0003-3830-5320
Baran, Natalia https://orcid.org/0000-0003-0618-4798
Harutyunyan, Karine
Cavazos, Antonio
Mallampati, Saradhi
Chin, Renee L
Jiang, Zhou https://orcid.org/0000-0003-4247-2949
Sun, Xian
Lee, Heng-Huan
Hsu, Jennifer L
Williams, Patrick
Huang, Xuelin
Curran, Michael A
Hung, Mien-Chie
Konopleva, Marina
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04329325 at ClinicalTrials.govnct02744768 at ClinicalTrials.govDocuments that mention this clinical trial
PD-1 blockade in combination with dasatinib potentiates induction of anti-acute lymphocytic leukemia immunity
https://doi.org/10.1136/jitc-2022-006619
nct03263572 at ClinicalTrials.govDocuments that mention this clinical trial
Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL
https://doi.org/10.1200/jco.23.01075
Dasatinib as an investigational drug for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults
https://doi.org/10.1080/13543784.2019.1597052
PD-1 blockade in combination with dasatinib potentiates induction of anti-acute lymphocytic leukemia immunity
https://doi.org/10.1136/jitc-2022-006619
nct02143414 at ClinicalTrials.govDocuments that mention this clinical trial
Subgroup analysis from a phase II trial of ponatinib and blinatumomab in relapsed/refractory (R/R) Philadelphia chromosome-positive acute lymphoblastic leukemia or chronic myeloid leukemia in lymphoid blast phase.
https://doi.org/10.1200/jco.2023.41.16_suppl.e19038
Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive ALL
https://doi.org/10.1200/jco.24.00272
PD-1 blockade in combination with dasatinib potentiates induction of anti-acute lymphocytic leukemia immunity
https://doi.org/10.1136/jitc-2022-006619
A phase II trial of ponatinib and blinatumomab in adults with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL).
https://doi.org/10.1200/jco.2023.41.16_suppl.e19013
nct03147612 at ClinicalTrials.govDocuments that mention this clinical trial
Dasatinib as an investigational drug for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults
https://doi.org/10.1080/13543784.2019.1597052
PD-1 blockade in combination with dasatinib potentiates induction of anti-acute lymphocytic leukemia immunity
https://doi.org/10.1136/jitc-2022-006619
nct03160079 at ClinicalTrials.govDocuments that mention this clinical trial
Low-intensity chemotherapy (mini-HCVD) and ponatinib followed by blinatumomab (blina) and ponatinib for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL): A phase II study.
https://doi.org/10.1200/jco.2023.41.16_suppl.e19028
PD-1 blockade in combination with dasatinib potentiates induction of anti-acute lymphocytic leukemia immunity
https://doi.org/10.1136/jitc-2022-006619
nct03512405 at ClinicalTrials.govDocuments that mention this clinical trial
PD-1 blockade in combination with dasatinib potentiates induction of anti-acute lymphocytic leukemia immunity
https://doi.org/10.1136/jitc-2022-006619
nct02879695 at ClinicalTrials.govDocuments that mention this clinical trial
PD-1 blockade in combination with dasatinib potentiates induction of anti-acute lymphocytic leukemia immunity
https://doi.org/10.1136/jitc-2022-006619
Documents that mention this clinical trial
Monoclonal antibodies: new chance in the management of B-cell acute lymphoblastic leukemia
https://doi.org/10.1080/16078454.2022.2074704
PD-1 blockade in combination with dasatinib potentiates induction of anti-acute lymphocytic leukemia immunity
https://doi.org/10.1136/jitc-2022-006619
-
Funding
Funding for this research was provided by:
University of Texas MD Anderson Cancer Center Support Grant (CA016672)
University of Texas MD Anderson–China Medical University and Hospital Sister Institution Network Fund (N/A)
Advanced Scholar Program at MD Anderson (2018-2019, Koller)
- License Information
